Regenerative MedicineHow Bimagrumab Targets Muscle Loss and Obesity From Lab Bench to Clinical Trial
In this two-and-a-half-hour episode, Peter Attia and physician-scientist Lloyd Klickstein trace every step of modern drug development using bimagrumab — an antibody that blocks myostatin and activin signaling — as the central example. Klickstein explains how sarcopenia was chosen as an initial target, how the antibody was engineered and screened, and what early animal data showed regarding dramatic muscle hypertrophy. He then walks through first-in-human studies, Phase 2 lessons on muscle function and nutrition, and a surprising finding: bimagrumab also reduced fat mass and improved type 2 diabetes markers. This pivot led to the BELIEVE trial combining bimagrumab with semaglutide. The conversation also covers the economics of drug development, patent strategy, GMP manufacturing, IND requirements, selective mTORC1 inhibition, and an emerging pharmacologic approach to cancer prevention.
